High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
- PMID: 30753505
- DOI: 10.1093/jac/dkz030
High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
Abstract
Objectives: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial.
Methods: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST.
Results: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235.
Conclusions: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01589-17. doi: 10.1128/AAC.01589-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28874376 Free PMC article.
-
High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.J Antimicrob Chemother. 2017 Dec 1;72(12):3277-3282. doi: 10.1093/jac/dkx322. J Antimicrob Chemother. 2017. PMID: 28961773 Free PMC article.
-
Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835. doi: 10.1093/jac/dkz147. J Antimicrob Chemother. 2019. PMID: 30989186
-
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents. 2020 Dec;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196. Epub 2020 Oct 9. Int J Antimicrob Agents. 2020. PMID: 33045347 Review.
-
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.Infection. 2021 Jun;49(3):549-553. doi: 10.1007/s15010-020-01539-9. Epub 2020 Oct 19. Infection. 2021. PMID: 33074365 Free PMC article. Review.
Cited by
-
Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran.BMC Res Notes. 2020 Aug 10;13(1):380. doi: 10.1186/s13104-020-05224-w. BMC Res Notes. 2020. PMID: 32778154 Free PMC article.
-
Phenotypic and genotypic within-host diversity of Pseudomonas aeruginosa urinary isolates.Sci Rep. 2022 Mar 30;12(1):5421. doi: 10.1038/s41598-022-09234-5. Sci Rep. 2022. PMID: 35354853 Free PMC article.
-
Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018-2019.Emerg Infect Dis. 2022 Jan;28(1):51-61. doi: 10.3201/eid2801.211880. Emerg Infect Dis. 2022. PMID: 34932447 Free PMC article. Review.
-
Quercetin: a promising virulence inhibitor of Pseudomonas aeruginosa LasB in vitro.Appl Microbiol Biotechnol. 2024 Dec;108(1):57. doi: 10.1007/s00253-023-12890-w. Epub 2024 Jan 5. Appl Microbiol Biotechnol. 2024. PMID: 38180553 Free PMC article.
-
High-risk Pseudomonas aeruginosa clones harboring β-lactamases: 2024 update.Heliyon. 2024 Dec 26;11(1):e41540. doi: 10.1016/j.heliyon.2024.e41540. eCollection 2025 Jan 15. Heliyon. 2024. PMID: 39850428 Free PMC article.